p53, guardian of the genome
The DOI matches its Crossref record; 19 of the 19 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“p53, famously known as the ‘Guardian of the genome’ plays a key role in manifestation of cellular senescence via several different mechanisms (Lane, 1992; Kastenhuber and Lowe, 2017).”
From Mechanisms of Cellular Senescence: Cell Cycle Arrest and Senescence Associated Secretory Phenotype (2021) · cites this paper as Lane, 1992
In the citing paper
“p53 is an crucial tumor suppressor that is mutated in more than 50% of human cancers”
From USP10 Regulates p53 Localization and Stability by Deubiquitinating p53 (2010) · cites this paper as Lane, 1992
Citations
Cites
p53 Mutations in Human Cancers
Hollstein, M., Sidransky, D., Vogelstein, B., & Harris, C. C. (1991) · Science · doi:10.1126/science.1905840 · Cited by 8,018
Mice deficient for p53 are developmentally normal but susceptible to spontaneous tumours
Donehower, L. A., Harvey, M., Slagle, B. L., McArthur, M. J., Montgomery, C. A., Butel, J. S., & Bradley, A. (1992) · Nature · doi:10.1038/356215a0 · Cited by 4,649
Participation of p53 protein in the cellular response to DNA damage.
Kastan, M. B., Onyekwere, O. C., Sidransky, D., Vogelstein, B., & Craig, R. W. (1991) · PubMed · Cited by 3,761
Momand, J., Zambetti, G. P., Olson, D. C., George, D., & Levine, A. J. (1992) · Cell · doi:10.1016/0092-8674(92)90644-r · Cited by 3,113
Wild-type p53 induces apoptosis of myeloid leukaemic cells that is inhibited by interleukin-6
Yonish-Rouach, E., Resnftzky, D., Lotem, J., Sachs, L., Kimchi, A., & Oren, M. (1991) · Nature · doi:10.1038/352345a0 · Cited by 2,079
Definition of a consensus binding site for p53
El-Deiry, W. S., Kern, S. E., Pietenpol, J. A., Kinzler, K. W., & Vogelstein, B. (1992) · Nature Genetics · doi:10.1038/ng0492-45 · Cited by 1,985
Amplification of a gene encoding a p53-associated protein in human sarcomas
Oliner, J. D., Kinzler, K. W., Meltzer, P. S., George, D. L., & Vogelstein, B. (1992) · Nature · doi:10.1038/358080a0 · Cited by 1,949
Identification of p53 as a Sequence-Specific DNA-Binding Protein
Kern, S. E., Kinzler, K. W., Bruskin, A., Jarosz, D., Friedman, P., Prives, C., & Vogelstein, B. (1991) · Science · doi:10.1126/science.2047879 · Cited by 1,085
Oncogenic forms of p53 inhibit p53-regulated gene expression
Kern, S., Pietenpol, J., Thiagalingam, S., Seymour, A., Kinzler, K., & Vogelstein, B. (1992) · Science · doi:10.1126/science.1589764 · Cited by 940
UV irradiation stimulates levels of p53 cellular tumor antigen in nontransformed mouse cells.
Maltzman, W., & Czyzyk, L. (1984) · Molecular and Cellular Biology · doi:10.1128/mcb.4.9.1689 · Cited by 893
Research works printed but not linked: 3
- Sturzbecher, H.-W. Oncogene (in the press).
- Kastan, M. B., Onyekwere, O., Sidransky, D., Vogelstein, B. & Craig, R. W. Cancer Res. 51, 6304–6311 (1991).
- Bischoff, F. Z. et al. Cancer Res. 50, 7979–7984 (1990).
Cited by
Items 601–700 of 1,031
High-LET radiation enhanced apoptosis but not necrosis regardless of p53 status
Takahashi, A., Matsumoto, H., Yuki, K., Yasumoto, J.-I., Kajiwara, A., Aoki, M., Furusawa, Y., Ohnishi, K., & Ohnishi, T. (2004) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2004.05.062 · Cited by 127
The Oscar-worthy role of Myc in apoptosis
Meyer, N., Kim, S. S., & Penn, L. Z. (2006) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2006.07.011 · Cited by 158
Protein phosphatase 1 interacts with p53BP2, a protein which binds to the tumour suppressor p53
(1995) · FEBS Letters · doi:10.1016/0014-5793(95)01347-4 · Cited by 129
Kovach, J. S., Hartmann, A., Blaszyk, H., Cunningham, J. M., Schaid, D. J., & Sommer, S. S. (1996) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.93.3.1093 · Cited by 127
p53 overexpression in head and neck squamous cell carcinoma: Review of the literature
Raybaud-Diogène, H., Têtu, B., Morency, R., Fortin, A., & Monteil, R. A. (1996) · European Journal of Cancer Part B Oral Oncology · doi:10.1016/0964-1955(95)00095-x · Cited by 127
HLA-B-associated transcript 3 (Bat3)/Scythe is essential for p300-mediated acetylation of p53
Sasaki, T., Gan, E. C., Wakeham, A., Kornbluth, S., Mak, T. W., & Okada, H. (2007) · Genes & Development · doi:10.1101/gad.1534107 · Cited by 128
“The tumor suppressor protein p53 is a key guardian of genomic stability (Lane 1992).”
BackgroundP53 aggregation, interactions with tau, and impaired DNA damage response in Alzheimer’s disease
Farmer, K. M., Ghag, G., Puangmalai, N., Montalbano, M., Bhatt, N., & Kayed, R. (2020) · Acta Neuropathologica Communications · doi:10.1186/s40478-020-01012-6 · Cited by 127
“Western blot analysis of MDM2 with human AD and control brain demonstrates no significant difference in total MDM2 levels at the full-length (90kD) or caspase-3 apoptotic fragment (60 kD) (Fig.”
BackgroundInfluentialFour p53 DNA-binding domain peptides bind natural p53-response elements and bend the DNA.
Balagurumoorthy, P., Sakamoto, H., Lewis, M. S., Zambrano, N., Clore, G. M., Gronenborn, A. M., Appella, E., & Harrington, R. E. (1995) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.92.19.8591 · Cited by 126
p53 induces the expression of its antagonist p73ΔN, establishing an autoregulatory feedback loop
Kartasheva, N. N., Contente, A., Lenz-Stöppler, C., Roth, J. C., & Dobbelstein, M. (2002) · Oncogene · doi:10.1038/sj.onc.1205584 · Cited by 156
“…older way of controlling p53 activity, whereas mdm2 evolved more recently. p53 has long been known as the central ‘guardian of the genome’ (Lane, 1992), coordinating a response of the cell to genotoxic stress (Oren, 1999; Vogelstein et al., 2000) and protecting the organism against…”
BackgroundYuan, A. (2002) · Journal of Clinical Oncology · doi:10.1200/jco.20.4.900 · Cited by 120
Fernandez, S. V., Russo, I. H., & Russo, J. (2005) · International Journal of Cancer · doi:10.1002/ijc.21590 · Cited by 126
Teifke, J. P., & Löhr, C. V. (1996) · Journal of Comparative Pathology · doi:10.1016/s0021-9975(96)80010-7 · Cited by 126
Nakopoulou, L., Vourlakou, C., Zervas, A., Τζώνου, Α., Gakiopoulou, H., & Dimopoulos, M. A. (1998) · Human Pathology · doi:10.1016/s0046-8177(98)90225-8 · Cited by 125
Oligomerization Is Required for p53 to be Efficiently Ubiquitinated by MDM2
Maki, C. G. (1999) · Journal of Biological Chemistry · doi:10.1074/jbc.274.23.16531 · Cited by 126
Regulation of synoviocyte proliferation, apoptosis, and invasion by the p53 tumor suppressor gene.
Aupperle, K. R., Boyle, D. L., Hendrix, M. J. C., Seftor, E. A., Zvaifler, N. J., Barbosa, M. S., & Firestein, G. S. (1998) · Europe PMC (PubMed Central) · Cited by 125
Brady, H. J. M., Salomons, G. S., Bobeldijk, R. C., & Berns, A. J. M. (1996) · The EMBO Journal · doi:10.1002/j.1460-2075.1996.tb00463.x · Cited by 126
Botanical antioxidants for chemoprevention of photocarcinogenesis
Afaq, F. (2002) · Frontiers in Bioscience · doi:10.2741/afaq · Cited by 125
Chang, H., Sloan, S., Li, D., & Keith Stewart, A. (2004) · British Journal of Haematology · doi:10.1111/j.1365-2141.2004.05199.x · Cited by 126
“282 ª 2004 Blackwell Publishing Ltd, British Journal of Haematology, 127, 280–284 et al, 2004c). p53 function may be compromised by the presence of gene deletion, such as the loss of its function as the ‘guardian of the genome’ (Lane, 1992).”
BackgroundDoglioni, C., Tos, A. P. D., Laurino, L., Chiarelli, C., Barbareschi, M., & Viale, G. (1994) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/bf00197392 · Cited by 129
“1985) not only inhibits cell proliferation (Lane 1992), but has been also shown to induce apoptosis in a leukaemic cell line (Yonish-Rouach et al.”
BackgroundChen, X., Farmer, G., Zhu, H., Prywes, R., & Prives, C. (1993) · Genes & Development · doi:10.1101/gad.7.10.1837 · Cited by 123
Gollner, A., Rudolph, D., Arnhof, H., Bauer, M., Blake, S. M., Boehmelt, G., Cockroft, X.-L., Dahmann, G., Ettmayer, P., Gerstberger, T., et al. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.6b00900 · Cited by 121
State of the art in medical applications using non-thermal atmospheric pressure plasma
Tanaka, H., Ishikawa, K., Mizuno, M., Toyokuni, S., Kajiyama, H., Kikkawa, F., Metelmann, H., & Hori, M. (2017) · Reviews of Modern Plasma Physics · doi:10.1007/s41614-017-0004-3 · Cited by 135
Palanikumar, L., Karpauskaite, L., Al-Sayegh, M., Chehade, I., Alam, M., Hassan, S., Maity, D., Ali, L., Kalmouni, M., Hunashal, Y., et al. (2021) · Nature Communications · doi:10.1038/s41467-021-23985-1 · Cited by 132
(1999) · PubMed · Cited by 123
Mutations of the p53 gene in myelodysplastic syndrome (MDS) and MDS- derived leukemia
Sugimoto, K., Hirano, N., Toyoshima, H., Chiba, S., Mano, H., Takaku, F., Yazaki, Y., & Hirai, H. (1993) · Blood · doi:10.1182/blood.v81.11.3022.3022 · Cited by 123
A novel HER2-positive breast cancer phenotype arising from germline TP53 mutations: Table 1
Wilson, J. R. F., Bateman, A. C., Hanson, H., An, Q., Evans, G., Rahman, N., Jones, J. L., & Eccles, D. M. (2010) · Journal of Medical Genetics · doi:10.1136/jmg.2010.078113 · Cited by 122
Regulation of MDMX nuclear import and degradation by Chk2 and 14-3-3
LeBron, C., Chen, L., Gilkes, D. M., & Chen, J. (2006) · The EMBO Journal · doi:10.1038/sj.emboj.7601032 · Cited by 122
Gudkov, A. V., Kazarov, A. R., Thimmapaya, R., Axenovich, S. A., Mazo, I. A., & Roninson, I. B. (1994) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.91.9.3744 · Cited by 122
Naidu, S. R., Love, I. M., Imbalzano, A. N., Grossman, S. R., & Androphy, E. J. (2009) · Oncogene · doi:10.1038/onc.2009.121 · Cited by 122
“…uthor M anuscript A uthor M anuscript Introduction Diverse stress signaling pathways converge on the tumor suppressor p53, which orchestrates a transcription program to maintain genome integrity by inducing growth arrest, replicative senescence or apoptosis (Lane, 1992; Vousden and Lane, 2007).”
p53 and p21 Regulate Error-Prone DNA Repair to Yield a Lower Mutation Load
Avkin, S., Sevilya, Z., Toube, L., Geacintov, N. E., Chaney, S. G., Oren, M., & Livneh, Z. (2006) · Molecular Cell · doi:10.1016/j.molcel.2006.03.022 · Cited by 141
Cancer genetics: from Boveri and Mendel to microarrays
Balmain, A. (2001) · Nature reviews. Cancer · doi:10.1038/35094086 · Cited by 169
p53 mutation and MDM2 amplification frequency in pediatric rhabdomyosarcoma tumors and cell lines
Taylor, A. C., Shu, L., Danks, M. K., Poquette, C. A., Shetty, S., Thayer, M. J., Houghton, P. J., & Harris, L. C. (2000) · Medical and Pediatric Oncology · doi:10.1002/1096-911x(200008)35:2<96::aid-mpo2>3.0.co;2-z · Cited by 125
Stemmermann, G. N., Heffelfinger, S. C., Noffsinger, A. E., Hui, Y. Z., Miller, M. A., & Fenoglio‐Preiser, C. M. (1994) · Human Pathology · doi:10.1016/0046-8177(94)90056-6 · Cited by 122
Scotin, a novel p53-inducible proapoptotic protein located in the ER and the nuclear membrane
Bourdon, J.-C., Renzing, J., Robertson, P. L., Fernandes, K. N., & Lane, D. P. (2002) · The Journal of Cell Biology · doi:10.1083/jcb.200203006 · Cited by 123
“Thus, p53 functions as a “guardian of the genome” (Lane, 1992). p53 can act as a transcription factor that, in response to cellular stress, binds DNA in a sequence-specific manner and induces the expression of genes containing a p53 bindingsite element in their promoter or introns (El-Deiry et al.,…”
BackgroundSelf-citationAbsence of p53 allows direct immortalization of hematopoietic cells by the myc and raf oncogenes
Metz, T. M., Harris, A. W., & Adams, J. M. (1995) · Cell · doi:10.1016/0092-8674(95)90049-7 · Cited by 123
Fatty-acid metabolism and the pathogenesis of hepatocellular carcinoma: Review and hypothesis
Ockner, R. K., Kaikaus, R. M., & Bass, N. M. (1993) · Hepatology · doi:10.1002/hep.1840180327 · Cited by 121
Tyrosinase Gene Expression is Regulated by p53
Khlgatian, M. K., Hadshiew, I., Asawanonda, P., Yaar, M., Eller, M. S., Gilchrest, B. A., Fujita, M., & Norris, D. A. (2002) · Journal of Investigative Dermatology · doi:10.1046/j.0022-202x.2001.01667.x · Cited by 130
Transcriptional repression of the human p53 gene by hepatitis B viral X protein
Lee, S., & Rho, H. M. (2000) · Oncogene · doi:10.1038/sj.onc.1203312 · Cited by 127
“Wild type p53 is a tumor suppressor protein that induces either apoptosis or cell cycle arrest at the G1-S checkpoint in response to DNA damage, thus preventing the transmission of genetic mutations to the daughter cells (Lane, 1992).”
BackgroundSpontaneous and ionizing radiation-induced chromosomal abnormalities in p53-deficient mice.
Bouffler, S. D., Kemp, C. J., Balmain, A., & Cox, R. (1995) · PubMed · Cited by 121
Gomyo, Y., Ikeda, M., Osaki, M., Tatebe, S., Tsujitani, S., Ikeguchi, M., Kaibara, N., & Ito, H. (1997) · Cancer · doi:10.1002/(sici)1097-0142(19970601)79:11<2067::aid-cncr3>3.0.co;2-m · Cited by 121
Evaluation of high-throughput genotoxicity assays used in profiling the US EPA ToxCast™ chemicals
Knight, A. W., Little, S. B., Houck, K. A., Dix, D. J., Judson, R., Richard, A., McCarroll, N., Akerman, G. S., Yang, C., Birrell, L., et al. (2009) · Regulatory Toxicology and Pharmacology · doi:10.1016/j.yrtph.2009.07.004 · Cited by 123
Mitochondrial dysfunction in cancer
Księżakowska-Łakoma, K., Żyła, M., & R. Wilczyński, J. (2014) · Menopausal Review · doi:10.5114/pm.2014.42717 · Cited by 121
“In response to a spectrum of apoptotic stimuli such as oxidative stress p53 translocates to mitochondria where it displaces anti-apoptotic channel-forming proteins [126-129].”
Yoshimura, S., Morishita, R., Hayashi, K., Yamamoto, K., Nakagami, H., Kaneda, Y., Sakai, N., & Ogihara, T. (2001) · Gene Therapy · doi:10.1038/sj.gt.3301566 · Cited by 121
The Y-box-binding Protein, YB1, Is a Potential Negative Regulator of the p53 Tumor Suppressor
Lasham, A., Moloney, S., Hale, T. K., Homer, C. R., Zhang, Y. F., Murison, J. G., Braithwaite, A. W., & Watson, J. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m303920200 · Cited by 151
The Function of the Mutant p53-R175H in Cancer
Chiang, Y.-T., Chien, Y.-C., Lin, Y.-H., Wu, H.-H., Lee, D.-F., & Yu, Y.-L. (2021) · Cancers · doi:10.3390/cancers13164088 · Cited by 117
Lu, Y.-P., Lou, Y. R., Li, X. H., Xie, J., Brash, D. E., Huang, M.-N., & Conney, A. H. (2000) · PubMed · Cited by 127
Martoriati, A., Doumont, G., Alcalay, M., Bellefroid, E., Pelicci, P. G., & Marine, J. (2004) · Oncogene · doi:10.1038/sj.onc.1208256 · Cited by 128
“…prevents cancer development by inhibiting the proliferation of stressed or abnormal cells (Levine, 1997). p53 functions as a sequence-specific DNAbinding transcription factor that promotes antiproliferative responses, including cell-cycle checkpoints, cellular senescence and apoptosis (Lane, 1992).”
BackgroundRhodes, L. E. (2003) · Carcinogenesis · doi:10.1093/carcin/bgg038 · Cited by 118
Zhu, Y.-M., Das-Gupta, E. P., & Russell, N. H. (1999) · Blood · doi:10.1182/blood.v94.2.733 · Cited by 118
Watson, W. H., Cai, J., & Jones, D. P. (2000) · Annual Review of Nutrition · doi:10.1146/annurev.nutr.20.1.485 · Cited by 118
The p53 Status of Chinese Hamster V79 Cells Frequently Used for Studies on DNA Damage and DNA Repair
Chaung, W., Mi, L.-J., & Boorstein, R. J. (1997) · Nucleic Acids Research · doi:10.1093/nar/25.5.992 · Cited by 118
Treatment Optimization Using Physical and Radiobiological Objective Functions
Brahme, A. (1995) · Medical radiology · doi:10.1007/978-3-662-03107-0_11 · Cited by 118
p53: A Cell Cycle Regulator Activated by DNA Damage
Selivanova, G., & Wiman, K. G. (1995) · Advances in cancer research · doi:10.1016/s0065-230x(08)60253-5 · Cited by 128
Regulation of DNA damage recognition and nucleotide excision repair: another role for p53
Ford, J. M. (2005) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2005.04.005 · Cited by 117
α-Helix mimetics: Outwards and upwards
Jayatunga, M. K. P., Thompson, S., & Hamilton, A. D. (2013) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2013.12.003 · Cited by 122
2-Sulfonylpyrimidines: Mild alkylating agents with anticancer activity toward p53-compromised cells
Bauer, M. R., Joerger, A. C., & Fersht, A. R. (2016) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1610421113 · Cited by 117
DNA-damaging agents cause inactivation of translational regulators linked to mTOR signalling
Tee, A. R., & Proud, C. G. (2000) · Oncogene · doi:10.1038/sj.onc.1203622 · Cited by 135
“Cells with extensive DNA damage may enter a series of events which results in programmed cell death (apoptosis) (Clarke et al., 1993; Lowe et al., 1993), which generally involves caspase activation (Sun et al., 1999) thereby preventing the proliferation of genetically damaged cells (Lane, 1992).”
BackgroundSystemic DNA damage responses in aging and diseases
Ribezzo, F., Shiloh, Y., & Schumacher, B. (2016) · Seminars in Cancer Biology · doi:10.1016/j.semcancer.2015.12.005 · Cited by 116
The G2 Checkpoint Is Maintained by Redundant Pathways
Passalaris, T. M., Benanti, J. A., Gewin, L., Kiyono, T., & Galloway, D. A. (1999) · Molecular and Cellular Biology · doi:10.1128/mcb.19.9.5872 · Cited by 116
Nanocosmetics and Nanomedicines
(2011) · doi:10.1007/978-3-642-19792-5 · Cited by 116
p53: The barrier to cancer stem cell formation
Aloni-Grinstein, R., Shetzer, Y., Kaufman, T., & Rotter, V. (2014) · FEBS Letters · doi:10.1016/j.febslet.2014.02.011 · Cited by 133
The nucleolus as a fundamental regulator of the p53 response and a new target for cancer therapy
Woods, S. J., Hannan, K. M., Pearson, R. B., & Hannan, R. D. (2014) · Biochimica et Biophysica Acta (BBA) - Gene Regulatory Mechanisms · doi:10.1016/j.bbagrm.2014.10.007 · Cited by 128
Logic-based models in systems biology: a predictive and parameter-free network analysis method
Wynn, M. L., Consul, N., Merajver, S. D., & Schnell, S. D. (2012) · Integrative Biology · doi:10.1039/c2ib20193c · Cited by 136
A matter of death and life: the significance of germ cell death during spermatogenesis
BLANCO‐RODRÍGUEZ (1998) · International Journal of Andrology · doi:10.1046/j.1365-2605.1998.00133.x · Cited by 126
p53 -Dependent and -Independent Nucleolar Stress Responses
Olausson, K. H., Nistér, M., & Lindström, M. S. (2012) · Cells · doi:10.3390/cells1040774 · Cited by 137
p53: Twenty five years understanding the mechanism of genome protection
Gómez-Lázaro, M., Fernández-Gómez, F.-J., & Jordán, J. (2004) · Journal of Physiology and Biochemistry · doi:10.1007/bf03167075 · Cited by 134
Tumourigenesis associated with the p53 tumour suppressor gene
Chang, F., Syrjänen, S., Tervahauta, A. I., & Syrjänen, K. J. (1993) · British Journal of Cancer · doi:10.1038/bjc.1993.404 · Cited by 138
Involvement of p53 in DNA Strand Break‐induced Apoptosis in Postmitotic CNS Neurons
Enokido, Y., Araki, T., Tanaka, K., Aizawa, S., & Hatanaka, H. (1996) · European Journal of Neuroscience · doi:10.1111/j.1460-9568.1996.tb01325.x · Cited by 130
Pap, T., Aupperle, K. R., Gay, S., Firestein, G. S., & Gay, R. E. (2001) · Arthritis & Rheumatism · doi:10.1002/1529-0131(200103)44:3<676::aid-anr117>3.0.co;2-6 · Cited by 116
P53 Dysfunction in Neurodegenerative Diseases - The Cause or Effect of Pathological Changes?
Szybińska, A., & Leśniakx, L. (2017) · Aging and disease · doi:10.14336/ad.2016.1120 · Cited by 116
Role of p53 in the Regulation of the Inflammatory Tumor Microenvironment and Tumor Suppression
Uehara, I., & Tanaka, N. (2018) · Cancers · doi:10.3390/cancers10070219 · Cited by 115
p53-A natural cancer killer: Structural insights and therapeutic concepts
Römer, L., Klein, C., Dehner, A., Kessler, H., & Buchner, J. (2006) · Angewandte Chemie International Edition · doi:10.1002/anie.200600611 · Cited by 93
Robert, C., Muel, B., Benoit, A., Dubertret, L., Sarasin, A. R., & Stary, A. (1996) · Journal of Investigative Dermatology · doi:10.1111/1523-1747.ep12345616 · Cited by 125
Expression of p53 protein in precursor lesions and adenocarcinoma of human pancreas.
Boschman, C. R., Stryker, S. J., Reddy, J. K., & Rao, M. S. (1994) · PubMed Central · Cited by 115
Achanta, G., Pelicano, H., Feng, L., Plunkett, W. K., & Huang, P. (2001) · PubMed · Cited by 148
Ashcroft, G. S., Herrick, S. E., Tarnuzzer, R. W., Horan, M. A., Schultz, G. S., & Ferguson, M. W. J. (1997) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199710)183:2<169::aid-path915>3.0.co;2-q · Cited by 121
The Role of the p53 Tumor Suppressor Gene in Squamous Cell Carcinoma of the Head and Neck
Field, J. K., Pavelić, Z. P., Spandidos, D. A., Stambrook, P. J., Jones, A., & Gluckman, J. L. (1993) · Archives of Otolaryngology - Head and Neck Surgery · doi:10.1001/archotol.1993.01880220064009 · Cited by 127
Spurgers, K. B., Gold, D. L., Coombes, K. R., Bohnenstiehl, N. L., Mullins, B., Meyn, R. E., Logothetis, C. J., & McDonnell, T. J. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m513901200 · Cited by 114
Gastric Cancer in the Era of Precision Medicine
Liu, X., & Meltzer, S. J. (2017) · Cellular and Molecular Gastroenterology and Hepatology · doi:10.1016/j.jcmgh.2017.02.003 · Cited by 135
Hamet, P. (1996) · Hypertension · doi:10.1161/01.hyp.28.3.321 · Cited by 114
p53 and the Li-Fraumeni syndrome
Malkin, D. M. (1994) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/0304-419x(94)90014-0 · Cited by 134
Chemoprevention of rat liver toxicity and carcinogenesis by Spirulina
Ismail, M. F., Ali, D. A., Fernando, A., Abdraboh, M. E., Gaur, R. L., Ibrahim, W. M., Raj, M. H., & Ouhtit, A. (2009) · International Journal of Biological Sciences · doi:10.7150/ijbs.5.377 · Cited by 113
Beyer, U., Moll-Rocek, J., Moll, U. M., & Dobbelstein, M. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1016201108 · Cited by 114
Savior and slayer: the two faces of p53
Bensaad, K., & Vousden, K. H. (2005) · Nature Medicine · doi:10.1038/nm1205-1278 · Cited by 138
Zinc deficiency and neurodevelopment: The case of neurons
Adamo, A. M., & Oteiza, P. I. (2010) · BioFactors · doi:10.1002/biof.91 · Cited by 122
Ren, J., Datta, R., Shioya, H., Li, Y., Oki, E., Biedermann, V., Bharti, A. K., & Kufe, D. W. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m110667200 · Cited by 114
Koivisto, P. A., & Rantala, I. S. (1999) · The Journal of Pathology · doi:10.1002/(sici)1096-9896(199901)187:2<191::aid-path206>3.0.co;2-3 · Cited by 49
Neilsen, P. M., Noll, J. E., Suetani, R. J., Schulz, R. B., Al-Ejeh, F., Evdokiou, A., Lane, D. P., & Callen, D. F. (2011) · Oncotarget · doi:10.18632/oncotarget.382 · Cited by 112
Self-citationp53 on the crossroad between regeneration and cancer
Charni, M., Aloni-Grinstein, R., Molchadsky, A., & Rotter, V. (2017) · Cell Death & Differentiation · doi:10.1038/cdd.2016.117 · Cited by 111
Oxidative stress is involved in the UV activation of p53
Renzing, J., Hansen, S., & Lane, D. P. (1996) · Journal of Cell Science · doi:10.1242/jcs.109.5.1105 · Cited by 113
Self-citationNegative effects of wild-type p53 and s-Myc on cellular growth and tumorigenicity of glioma cells
Asai, A., Miyagi, Y., Sugiyama, A., Gamanuma, M., Hong, S., Takamoto, S., Nomura, K., Matsutani, M., Takakura, K., & Kuchino, Y. (1994) · Journal of Neuro-Oncology · doi:10.1007/bf01053280 · Cited by 113
“However, recent studies revealed that the wt-p53 protein is a tumor suppressor, and functioning in preserving the genome physiologically [23-26].”
BackgroundRadford, I. R., & Murphy, T. K. (1994) · International Journal of Radiation Biology · doi:10.1080/09553009414550261 · Cited by 113
p53 and autophagy in cancer: Guardian of the genome meets guardian of the proteome
Ryan, K. M. (2010) · European Journal of Cancer · doi:10.1016/j.ejca.2010.10.020 · Cited by 129
Crosstalk between p53 and TGF-β Signalling
Elston, R., & Inman, G. J. (2012) · Journal of Signal Transduction · doi:10.1155/2012/294097 · Cited by 112
“This paper investigates the crosstalk between p53 and TGF-β signalling and the potential roles this plays in cancer biology.”
BackgroundRinon, A., Molchadsky, A., Nathan, E., Yovel, G., Rotter, V., Sarig, R., & Tzahor, E. (2011) · Development · doi:10.1242/dev.053645 · Cited by 112
“The tumor suppressor p53 (Trp53), which has been referred to as the ‘guardian of the genome’, plays key roles in the prevention of tumor development (Lane, 1992); however, its precise roles during embryogenesis remain to be elucidated.”
BackgroundLo, K. W.-H., Kan, H.-M., Chan, L.-N., Xu, W.-G., Wang, K.-P., Wu, Z., Sheng, M., & Zhang, M. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411408200 · Cited by 111
Molecular pathology of odontogenic tumors
Kumamoto, H. (2006) · Journal of Oral Pathology and Medicine · doi:10.1111/j.1600-0714.2006.00380.x · Cited by 118
Anderson, J. A., Lewellyn, A. L., & Maller, J. L. (1997) · Molecular Biology of the Cell · doi:10.1091/mbc.8.7.1195 · Cited by 113
Klammer, H., Mladenov, E., Li, F., & Iliakis, G. E. (2013) · Cancer Letters · doi:10.1016/j.canlet.2013.12.017 · Cited by 124
Hayashi, S.-I., Morishita, R., Matsushita, H., Nakagami, H., Taniyama, Y., Nakamura, T., Aoki, M., Yamamoto, K., Higaki, J., & Ogihara, T. (2000) · Hypertension · doi:10.1161/01.hyp.35.1.237 · Cited by 114
Metadata
- Authors
- Lane, D. P.
- Affiliations
- University of Dundee (GB)
- Corresponding author
- Lane, D. P.
- ORCID
- Lane, D. P.
- Venue
- Nature
- Published
- 1992-07
- Volume
- 358
- Issue
- 6381
- Pages
- 15-16
- ISSN
- 0028-0836 (ISSN-L)
- 1476-4687
- OpenAlex
- W2012053348
- Cited by
- 5,138
- References
- 19
- Citations by year
- 2026: 84 · 2025: 92 · 2024: 122 · 2023: 112 · 2022: 135 · 2021: 142 · 2020: 150 · 2019: 128 · 2018: 140 · 2017: 138 · 2016: 142 · 2015: 135 · 2014: 150 · 2013: 142 · 2012: 143
- FWCI
- 97.59
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer-related Molecular Pathways
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Chromatin Remodeling and Cancer
- Keywords
- TP53, p53, TP53 mutation, cancer, genome stability, tumor suppressor
- MeSH terms
- Animals, Chromosome Mapping, DNA Damage, DNA Repair, DNA-Binding Proteins, Gene Expression Regulation, Humans, Oncogenes, Transcription Factors, Genes, Tumor Suppressor, Tumor Suppressor Protein p53
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.